<?xml version='1.0' encoding='utf-8'?>
<document id="27873130"><sentence text="Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors."><entity charOffset="46-53" id="DDI-PubMed.27873130.s1.e0" text="PM01183" /><entity charOffset="57-79" id="DDI-PubMed.27873130.s1.e1" text="tetrahydroisoquinoline" /><entity charOffset="81-94" id="DDI-PubMed.27873130.s1.e2" text="Lurbinectedin" /><entity charOffset="116-127" id="DDI-PubMed.27873130.s1.e3" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e0" e2="DDI-PubMed.27873130.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e0" e2="DDI-PubMed.27873130.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e0" e2="DDI-PubMed.27873130.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e0" e2="DDI-PubMed.27873130.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e1" e2="DDI-PubMed.27873130.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e1" e2="DDI-PubMed.27873130.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e1" e2="DDI-PubMed.27873130.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e2" e2="DDI-PubMed.27873130.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27873130.s1.e2" e2="DDI-PubMed.27873130.s1.e3" /></sentence><sentence text="Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in patients with advanced solid tumors"><entity charOffset="70-77" id="DDI-PubMed.27873130.s2.e0" text="PM01183" /><entity charOffset="82-93" id="DDI-PubMed.27873130.s2.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.27873130.s2.e0" e2="DDI-PubMed.27873130.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27873130.s2.e0" e2="DDI-PubMed.27873130.s2.e1" /></sentence><sentence text=" Methods Forty-five patients received escalating doses of PM01183/gemcitabine on Days 1 and 8 every 3 weeks (d1,8 q3wk) following a standard 3 + 3 design"><entity charOffset="58-65" id="DDI-PubMed.27873130.s3.e0" text="PM01183" /><entity charOffset="66-77" id="DDI-PubMed.27873130.s3.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.27873130.s3.e0" e2="DDI-PubMed.27873130.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27873130.s3.e0" e2="DDI-PubMed.27873130.s3.e1" /></sentence><sentence text=" Results PM01183 3" /><sentence text="5 mg flat dose (FD)/gemcitabine 1000 mg/m2 was the highest dose level tested"><entity charOffset="20-31" id="DDI-PubMed.27873130.s5.e0" text="gemcitabine" /></sentence><sentence text=" Dose-limiting toxicities (DLTs) were mostly hematological and resulted in the expansion of a lower dose level (PM01183 3" /><sentence text="5 mg FD/gemcitabine 800 mg/m2); 19 patients at this dose level were evaluable but &gt;30% had DLT and &gt;20% had febrile neutropenia"><entity charOffset="8-19" id="DDI-PubMed.27873130.s7.e0" text="gemcitabine" /></sentence><sentence text=" No DLT was observed in 11 patients treated at PM01183 3" /><sentence text="0 mg FD/gemcitabine 800 mg/m2, which was defined as the RD"><entity charOffset="8-19" id="DDI-PubMed.27873130.s9.e0" text="gemcitabine" /></sentence><sentence text=" This regimen was feasible and tolerable with manageable toxicity; mainly grade 3/4 myelosuppression" /><sentence text=" Non-hematological toxicity comprised fatigue, nausea, vomiting, and transaminases increases" /><sentence text=" Fifteen (33%) patients received ≥6 cycles with no cumulative hematological toxicity" /><sentence text=" Pharmacokinetic analysis showed no evidence of drug-drug interaction" /><sentence text=" Nine of 38 patients had response as per RECIST (complete [3%] and partial [21%]), for an overall response rate (ORR) of 24% (95% Confidence Interval [CI] 12-40%)" /><sentence text=" Eleven patients (29%) had disease stabilization ≥4 months" /><sentence text=" Responses were durable (median of 8" /><sentence text="5 months): overall median progression-free survival (PFS) was 4" /><sentence text="2 months (95% CI, 2"><entity charOffset="14-16" id="DDI-PubMed.27873130.s18.e0" text="CI" /></sentence><sentence text="7-6" /><sentence text="5 months)" /><sentence text=" Conclusions The RD for this combination is PM01183 3" /><sentence text="0 mg FD (or 1" /><sentence text="6 mg/m2)/gemcitabine 800 mg/m2 d1,8 q3wk"><entity charOffset="9-20" id="DDI-PubMed.27873130.s23.e0" text="gemcitabine" /></sentence><sentence text=" This schedule is well tolerated and has antitumor activity in several advanced solid tumor types" /><sentence text="" /></document>